These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18830918)

  • 1. Retrovirus-induced oncogenesis and safety of retroviral vectors.
    Nair V
    Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retroviral vectors: post entry events and genomic alterations.
    Nowrouzi A; Glimm H; von Kalle C; Schmidt M
    Viruses; 2011 May; 3(5):429-55. PubMed ID: 21994741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
    Staal FJ; Pike-Overzet K; Ng YY; van Dongen JJ
    Leukemia; 2008 Oct; 22(10):1849-52. PubMed ID: 18769449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
    Trobridge GD
    Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel principles of gamma-retroviral insertional transcription activation in murine leukemia virus-induced end-stage tumors.
    Sokol M; Wabl M; Ruiz IR; Pedersen FS
    Retrovirology; 2014 May; 11():36. PubMed ID: 24886479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insertional oncogenesis by non-acute retroviruses: implications for gene therapy.
    Fan H; Johnson C
    Viruses; 2011 Apr; 3(4):398-422. PubMed ID: 21994739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
    Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
    PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retroviral Insertional Mutagenesis in Humans: Evidence for Four Genetic Mechanisms Promoting Expansion of Cell Clones.
    Bushman FD
    Mol Ther; 2020 Feb; 28(2):352-356. PubMed ID: 31951833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
    Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
    Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retroviral gene therapy: safety issues and possible solutions.
    Yi Y; Hahm SH; Lee KH
    Curr Gene Ther; 2005 Feb; 5(1):25-35. PubMed ID: 15638709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis.
    Knight S; Collins M; Takeuchi Y
    Curr Gene Ther; 2013 Jun; 13(3):211-27. PubMed ID: 23590635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
    Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
    Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
    Doi K; Takeuchi Y
    Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosafety considerations using gamma-retroviral vectors in gene therapy.
    Deichmann A; Schmidt M
    Curr Gene Ther; 2013 Dec; 13(6):469-77. PubMed ID: 24195605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.
    Deichmann A; Hacein-Bey-Abina S; Schmidt M; Garrigue A; Brugman MH; Hu J; Glimm H; Gyapay G; Prum B; Fraser CC; Fischer N; Schwarzwaelder K; Siegler ML; de Ridder D; Pike-Overzet K; Howe SJ; Thrasher AJ; Wagemaker G; Abel U; Staal FJ; Delabesse E; Villeval JL; Aronow B; Hue C; Prinz C; Wissler M; Klanke C; Weissenbach J; Alexander I; Fischer A; von Kalle C; Cavazzana-Calvo M
    J Clin Invest; 2007 Aug; 117(8):2225-32. PubMed ID: 17671652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial watch: Self-inactivating gene-therapy vector alleviates safety concerns.
    Cully M
    Nat Rev Drug Discov; 2014 Dec; 13(12):879. PubMed ID: 25394873
    [No Abstract]   [Full Text] [Related]  

  • 17. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
    Sinn PL; Sauter SL; McCray PB
    Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the genotoxic potential of retroviral vectors.
    Ramezani A; Hawley TS; Hawley RG
    Methods Mol Biol; 2008; 434():183-203. PubMed ID: 18470646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for severe combined immunodeficiencies and beyond.
    Fischer A; Hacein-Bey-Abina S
    J Exp Med; 2020 Jan; 217(2):. PubMed ID: 31826240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrome signatures of lentiviral gene therapy for SCID-X1 patients.
    Yan KK; Condori J; Ma Z; Metais JY; Ju B; Ding L; Dhungana Y; Palmer LE; Langfitt DM; Ferrara F; Throm R; Shi H; Risch I; Bhatara S; Shaner B; Lockey TD; Talleur AC; Easton J; Meagher MM; Puck JM; Cowan MJ; Zhou S; Mamcarz E; Gottschalk S; Yu J
    Sci Adv; 2023 Oct; 9(40):eadg9959. PubMed ID: 37801507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.